Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Durante

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Physical Therapy Science|February 11, 2020
The immediate effects of knee flexion range of motion following manual therapy or self-stretching/active range of motion following a total knee arthroplasty: a case reportThomas A Koc, Michael Durante, Inah A Bunales, et al.
Breast Cancer Research and Treatment|January 4, 2013
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerStephen R D Johnston, Henry Gómez, Salomon M Stemmer, et al.
Analytical Chemistry|April 2, 2013
Conversion strategy using an expanded genetic alphabet to assay nucleic acidsZunyi Yang, Michael Durante, Lyudmyla G Glushakova, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Physical Therapy Science|February 11, 2020
The immediate effects of knee flexion range of motion following manual therapy or self-stretching/active range of motion following a total knee arthroplasty: a case reportThomas A Koc, Michael Durante, Inah A Bunales, et al.
Breast Cancer Research and Treatment|January 4, 2013
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerStephen R D Johnston, Henry Gómez, Salomon M Stemmer, et al.
Analytical Chemistry|April 2, 2013
Conversion strategy using an expanded genetic alphabet to assay nucleic acidsZunyi Yang, Michael Durante, Lyudmyla G Glushakova, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Gastroenterology|September 8, 2019
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Pageof 2